Attorney Mistake Dooms Angiomax Patent Extension
The Medicines Co. disclosed Monday that the U.S. Patent and Trademark Office has rejected its application to extend its patent on the blood thinning drug Angiomax....To view the full article, register now.
Already a subscriber? Click here to view full article